Form 4: Director Jason Hannon Receives Orthofix Stock Award

Orthofix Medical Inc. director Jason Hannon was granted 14,965 deferred stock units as part of an equity compensation award.

Summary

• Director Jason Hannon acquired 14,965 deferred stock units (DSUs) on June 10, 2026.
• The DSUs represent a contingent right to receive one share of common stock per unit.
• The award vests in full on the first anniversary of the grant date, contingent upon continued service.
• Following this transaction, the reporting person's total beneficial ownership is 87,662 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• The director's increased equity stake aligns personal interests with long-term shareholder value.

Negatives

• None identified.

Risks

• Vesting of the deferred stock units is subject to the reporting person's continued service through the first anniversary of the grant date.

Future Outlook

The deferred stock units will vest on June 10, 2027, and will settle into common stock within 45 days of the director's eventual termination of service.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard corporate governance practice in the medical device industry to ensure director retention and alignment with long-term performance goals.

Comparison to Industry Standards

• The grant of deferred stock units is consistent with standard executive and director compensation packages among mid-cap medical technology firms.
• The vesting schedule of one year is typical for non-employee director equity awards in the healthcare sector.

Stakeholder Impact

• Shareholders may view the increased equity ownership by a director as a positive signal of confidence in the company's future.

Next Steps

• Vesting of the 14,965 deferred stock units on June 10, 2027.

Key Dates

Keywords

Orthofix Medical, OFIX, Form 4, Insider Transaction, Equity Compensation, Director Ownership